KELOWNA, BRITISH COLUMBIA -- (MARKET WIRE) -- October 23, 2006 -- Sernova Corp.'s (“Sernova”) (TSX VENTURE: SVA) cell replacement research for the company’s diabetes product development project is in line with the recently released recommendations of the US National Institute of Health’s (“NIH”) long range plan for diabetes research.
